Press release 📈 Stocks 🌍 United States

Actinium Pharmaceuticals Reports Q3 2026 Progress on ATNM-400 Pipeline

Actinium Pharmaceuticals advanced its ATNM-400 clinical program, clearing the 1.0 µCi/kg dose cohort in prostate cancer patients and initiating the RADIANZ pan-tumor imaging study, supported by a cash runway extending through 2027.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: ATNM → 3/10 (55% confidence).

📊 Affected Assets (1)

ATNM
Neutral 🤖 55%
📅 Short-term 🌍 US · Explicit

This is the company's own corporate update: HER3 disclosed as the ATNM-400 target, first HERACT-PRO-1 cohort cleared 1.0 µCi/kg with no dose-limiting toxicities, dose escalation at 1.5 µCi/kg, first RADIANZ patient dosed, and cash of $28.7 million as of September 30, 2026 funding operations through 2027. These are positive pipeline signals, but they are early Phase 1 safety and imaging findings without comparative efficacy figures, so they do not yet change the financial outlook. The stated cash runway through 2027 removes near-term financing pressure but also signals a small-cap burn profile.

Catalysts
  • • KOL webinar on ATNM-400 on December 1, 2026, 8:00 a.m. ET
  • • SABCS 2026 breast cancer preclinical poster on December 9, 2026
Risk Factors
  • • Only one cohort cleared at 1.0 µCi/kg with dose escalation still ongoing
  • • No efficacy or survival data reported, only imaging uptake through Day 7

🧭 Full analysis of these assets

🎯 Key Takeaways

  • The first cohort of the HERACT-PRO-1 study cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities.
  • Actinium reported $28.7 million in cash and cash equivalents as of September 30, 2026, sufficient to fund operations through 2027.
  • The company initiated the RADIANZ pan-tumor imaging study to evaluate HER3 targeting in lung, breast, colorectal, pancreatic, and ovarian cancers.
  • Dose escalation for ATNM-400 has advanced to the 1.5 µCi/kg level.

📝 Executive Summary

Actinium Pharmaceuticals provided a Q3 2026 update, highlighting the advancement of its HER3-targeted radiotherapy, ATNM-400. The company cleared the 1.0 µCi/kg dose level in its HERACT-PRO-1 study with no dose-limiting toxicities and initiated the RADIANZ pan-tumor imaging study. With $28.7 million in cash as of September 30, 2026, the company expects to fund operations through 2027.

❓ FAQ

Did Actinium report any hard results in this update?

The update reports that the first HERACT-PRO-1 cohort cleared the 1.0 µCi/kg dose level with no dose-limiting toxicities, imaging showed tumor uptake retained through Day 7, dose escalation has advanced to 1.5 µCi/kg, and cash of $28.7 million as of September 30, 2026 is expected to fund operations through 2027. No efficacy data or financial guidance figures were provided.

What is coming up that could move the stock?

Per the update: a KOL webinar on ATNM-400 on December 1, preclinical breast cancer data at SABCS 2026 on December 9, hematology program data at ASH 2026 December 12-15, and anticipated clinical data and development milestones across ATNM-400, Actimab-A and Iomab-ACT in 2027.